

08/133031

5630/5610  
10/25/93

#2

23 Rec'd PCT/PTO 1 3 OCT 1993

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of:	)	Office of the Deputy
LADNER, Robert C., et al.	)	Assistant Commissioner
Int. Appln. No.: PCT/US92/01501	)	for Patents
Filed: 28 February 1992	)	Washington, D.C.
For: INHIBITORS OF HUMAN	)	October 13, 1993
NEUTROPHIL ELASTASE AND	)	Dkt No.: LADNER 7C USA
HUMAN CATHEPSIN G	)	

PETITION TO REVIVE PCT APPLICATION UNDER 37 CFR 1.137(b)

Honorable Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

RECEIVED

RECEIVED

OCT 19 1993

NOV 5 1993

S i r :

OFFICE OF PETITIONS  
A/C PATENTS

OFFICE OF PETITIONS  
A/C PATENTS

Applicants, through their undersigned attorney, hereby petition for revival of the above identified PCT application in accordance with the terms of 37 CFR § 1.137(b), so that the application may be entered into the national stage. The above identified application became abandoned for failure to pay the basic national fee within the 30 month period set forth in 37 CFR § 1.495 (b), which ended on September 1, 1993.

Attached hereto in support of this Petition are the following:

(a) a request that the application be entered into the national stage;

(b) a small entity statement executed by an officer of Protein Engineering Corporation, the assignee;

(c) a preliminary amendment;

In re LADNER, Robert C. (based on PCT/US92/01501)

(d) a check (# 04055) in the amount of \$679.00 for the basic national fee, the expected additional claims fees, and the surcharge for late filing of the declaration all for a small entity, as set forth in 37 CFR 1.492, and

(e) a check (# 04050) in the amount of \$585.00 for the petition fee set forth in 37 CFR § 1.17 (m).

(f) copies of the PCT application as filed, the formal drawings filed with the Receiving Office on May 20, 1992, and the international preliminary examination report established by IPEA/EPO.

Any deficiency in the petition or filing fees required to revive this application and enter it into the national stage should be charged to Deposit Account 02-4035.

The abandonment, and the entire delay in paying the basic national fee, was unintentional. The present papers satisfy the requirements of 37 CFR § 1.495(b) to avoid abandonment of the application.

In order to avoid any delay in the filing of this Petition, it is being filed without a Declaration of the inventors. One of the inventors is not longer employed by the assignee, and her signature may therefore take some time to obtain. It is assumed that the USPTO will revive this application, enter it into the national stage, and send applicants the notice referred to in 37 CFR § 1.495(c)(2).

8801 VOW BO 771091240

In re LADNER, Robert C. (based on PCT/US92/01501)


The Declaration, is not required at this time to avoid abandonment. See 37 CFR § 1.495(c).

Granting of this petition and forwarding of the attached papers to the United States Elected Office for entry into the national stage is earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant

By:

  
Iver P. Cooper  
Reg. No. 28,005

Enclosures  
419 Seventh Street, N.W.  
Washington, D.C. 20004  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528  
IPC: jlr  
f:\user19\wp\ln-q\ladner7c.pet